USER EXPECTATIONS ON SMART TV; AN EMPIRIC STUDY ON USER EMOTIONS TOWARDS SMART TV

As a result of the introduction of new technologies in consumer electronics, analog TV shifted from a mere viewing experience to a personalized digital TV experience where users are encouraged to interact. The application of these new technologies not only create changes in physical appearance and adding more functionalities to TVs but it also shifts user expectations, which are mainly emotionally driven. The initial attempt of this study is to determine which emotions are involved in smart TV preference and why those particular emotions are aroused. In other words, this study aims to discover the link among contents, activities and user interaction as well as the relationship between triggered emotions and user expectations. By doing so, it analyses user emotions and expectations towards a dream TV. The primary data is collected towards semi-structured in-depth interviews. The results show that Smartness, High quality, Personalization, Functionality and Appearance are the key features that meet the expectations towards TV experience. User-friendliness, compatibleness, enjoyableness, awareness, novel-interactions, self-defense smart software and voice remote are the consequent expectations. All these expectations arise from different underlying emotional tendencies. With its initial attempt to propose guidelines for designers, this study suggests that for designing a smart TV that meets user expectations, its design should enable smart interaction that simplifies managing task (Smartness), high quality of picture and sound to enable innovative continuous experience (High quality), supporting not missing any content of interest and filter unwanted ones (Personalization), utilize all kinds of usage comfortably (Functionality), and should have an aesthetic look, even seamless design that fits any possible environment (Appearance).

An automation-based adaptive seamless design for dose selection and confirmation with improved power and efficiency

In a drug development program, the efficacy and safety of multiple doses can be evaluated in patients through a phase 2b dose ranging study. With a demonstrated dose response in the trial, promising doses are identified. Their effectiveness then is further investigated and confirmed in phase 3 studies. Although this two-step approach serves the purpose of the program, in general, it is inefficient because of its prolonged development duration and the exclusion of the phase 2b data in the final efficacy evaluation and confirmation which are only based on phase 3 data. To address the issue, we propose a new adaptive design, which seamlessly integrates the dose finding and confirmation steps under one pivotal study. Unlike existing adaptive seamless phase 2b/3 designs, the proposed design combines the response adaptive randomization, sample size modification, and multiple testing techniques to achieve better efficiency. The design can be easily implemented through an automated randomization process. At the end, a number of targeted doses are selected and their effectiveness is confirmed with guaranteed control of family-wise error rate.

Correlation of patient characteristics and biomarkers with clinical outcomes of JCAR017 in R/R aggressive B-NHL (TRANSCEND NHL 001 study).

122 Background: JCAR017 is a defined composition, CD19-directed 4-1BB CAR T cell product administered at a precise dose of CD8 and CD4 CAR T cells in a seamless design Ph1 pivotal trial of R/R B-cell NHL (TRANSCEND NHL 001; NCT02631044). Methods: Blood samples were collected for biomarker analyses at protocol-defined time points. PK (CAR T cell expansion and persistence) was measured using flow cytometry. Cytokines were measured on a Luminex platform. Additional analytes will be presented. All reported p-values are 2-sided without multiplicity adjustment. Results: Safety (n = 59) and efficacy (n = 54) outcomes were analyzed for correlations with patient (pt) characteristics and biomarkers. Dose level did not correlate with cytokine release syndrome (CRS) or neurotoxicity (NT) despite higher median Cmax and median AUC0-28 at DL2. In pts with NT or ≥Gr 2 CRS, CD4 and CD8 CAR T cell levels were 5-10 fold and 3-5 fold higher, respectively, than median DL2 levels. Pt factors that correlated with any grade CRS and NT were ECOG 2 (p = 0.03) and high disease burden (p < 0.05). Higher levels of IL-8, IL-10, and CXCL10 before CART cell infusion were associated with Gr 3-4 NT (each p< 0.05), suggesting that inherent pt factors may result in higher CAR T expansion and associated CRS and NT. Lower pre-CAR T cell ferritin, LDH, CXCL10, G-CSF, and IL-10 were associated with CR/PR, and lower pre-CAR T cell ferritin, CRP, LDH, CXCL10, IL-8, IL-10, IL-15, MCP-1, MIP-1β, TNF-α were associated with 3-month durable response (each p< 0.05). Median Cmax and AUC0-28 of CD8 CAR T cells were higher in responding patients and with durable response at Month 3 (CD8 Cmax median = 20.8 vs 5.5; CD8 AUC median = 235 vs 55 in CR/PR vs PD at Month 3). Of pts evaluable for persistence at 3 months (n = 29), 90% and 93% had detectable CD8+ and CD4+ CAR+ T cells; of those with available PK results at time of relapse (n = 11), 82% had persistence at time of relapse. Conclusions: JCAR017 demonstrated increased CAR T cell expansion and persistence and higher durability of response at higher dose levels, with manageable toxicities. CAR T cells were also detected at time of relapse, suggesting potential opportunities for future combination clinical trials. Clinical trial information: NCT02631044.